Grard AP. Nieuwenhuijzen

Feb 23, 2024 | ejso.com | Julie Geerts |Rob H.A. Verhoeven |Camiel Rosman |Bas PL Wijnhoven |Grard AP. Nieuwenhuijzen

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Feb 23, 2024 | ejso.com | Julie Geerts |Manon C. Spaander |Grard AP. Nieuwenhuijzen |Camiel Rosman |Hanneke van Laarhoven |Rob H.A. Verhoeven | +3 more

Background: Perioperative fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) became standard of care in most Western countries after the FLOT4-AIO trial (2019) showed improved survival compared to perioperative anthracycline triplets. The aim of this study is to compare outcomes of FLOT to anthracycline triplets in the Netherlands using real-world population level data.

Feb 23, 2024 | ejso.com | Julie Geerts |Rob H.A. Verhoeven |Camiel Rosman |Bas PL Wijnhoven |Grard AP. Nieuwenhuijzen

Background: The Egidius oesophageal/gastric project aims to improve the quality of care for oesophageal and gastric cancer patients at every stage of disease and treatment. Cross-regional and network-transcending multidisciplinary expert meetings were organized with both patients and physicians from departments of surgery, gastroenterology, medical oncology, and radiotherapy from three regions in the Netherlands.